Tisolagiline (monomethylsulfate)

Tisolagiline methylsulfate (KDS2010) is the selective, reversible and orally active inhibitor for MAO-B with an IC50 of 8 nM. Tisolagiline methylsulfate exhibits neuroprotective and anti-neuroinflammatory activities[1][2].

Product Specifications

CAS Number

[1894207-45-4]

Product Name Alternative

KDS2010 (monomethylsulfate)

UNSPSC

12352005

Target

Monoamine Oxidase

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Cancer-programmed cell death

Field of Research

Cancer; Neurological Disease

Assay Protocol

https://www.medchemexpress.com/tisolagiline-methylsulfate.html

Purity

99.83

Solubility

DMSO : 20 mg/mL (ultrasonic; adjust pH to 2 with 1 M HCL)

Smiles

C[C@H](NCC1=CC=C(C2=CC=C(C(F)(F)F)C=C2)C=C1)C(N)=O.CS(=O)(O)=O

Molecular Formula

C18H21F3N2O4S

Molecular Weight

418.43

References & Citations

[1]Nam MH, et al. KDS2010, a Newly Developed Reversible MAO-B Inhibitor, as an Effective Therapeutic Candidate for Parkinson's Disease. Neurotherapeutics. 2021 Jul;18 (3) :1729-1747.|[2]Diep YN, et al., Astrocytic scar restricting glioblastoma via glutamate-MAO-B activity in glioblastoma-microglia assembloid. Biomater Res. 2023 Jul 19;27 (1) :71